Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan
Status PubMed-not-MEDLINE Language English Country England, Great Britain Media electronic-ecollection
Document type Journal Article
PubMed
25228919
PubMed Central
PMC4162678
DOI
10.3332/ecancer.2014.463
PII: can-8-463
Knihovny.cz E-resources
- Keywords
- adult, anti-angiogenesis, cancer, child, drug repurposing, metronomic chemotherapy, pharmacoeconomics,
- Publication type
- Journal Article MeSH
The Fourth Metronomic and Anti-angiogenic Therapy Meeting was held in Milan 24-25 June 2014. The meeting was a true translational meeting where researchers and clinicians shared their results, experiences, and insights in order to continue gathering useful evidence on metronomic approaches. Several speakers emphasised that exact mechanisms of action, best timing, and optimal dosage are still not well understood and that the field would learn a lot from ancillary studies performed during the clinical trials of metronomic chemotherapies. From the pre-clinical side, new research findings indicate additional possible mechanisms of actions of metronomic schedule on the immune and blood vessel compartments of the tumour micro-environment. New clinical results of metronomic chemotherapy were presented in particular in paediatric cancers [especially neuroblastoma and central nervous system (CNS) tumours], in angiosarcoma (together with beta-blockers), in hepatocellular carcinoma, in prostate cancer, and in breast cancer. The use of repurposed drugs such as metformin, celecoxib, or valproic acid in the metronomic regimen was reported and highlighted the potential of other candidate drugs to be repurposed. The clinical experiences from low- and middle-income countries with affordable regimens gave very encouraging results which will allow more patients to be effectively treated in economies where new drugs are not accessible. Looking at the impact of metronomic approaches that have been shown to be effective, it was admitted that those approaches were rarely used in clinical practice, in part because of the absence of commercial interest for companies. However, performing well-designed clinical trials of metronomic and repurposing approaches demonstrating substantial improvement, especially in populations with the greatest unmet needs, may be an easier solution than addressing the financial issue. Metronomics should always be seen as a chance to come up with new innovative affordable approaches and not as a cheap rescue strategy.
Anticancer Fund Strombeek Bever B1853 Belgium
Cancer Institute 'I Chiricuta' Cluj Napoca 400015 Romania
Department of Mathematics and Statistics Southern Illinois University Edwardsville IL 62026 USA
Department of Paediatric Oncology University of Cologne D50924 Germany
Division of Experimental Therapeutics European Institute of Oncology Milan 20141 Italy
Division of Medical Senology European Institute of Oncology Milan 20141 Italy
Laboratory of Haematology Oncology European Institute of Oncology Milan 20141 Italy
Medical Oncology Department Brindisi 72100 Italy
Molecular Medicine Programme European Institute of Oncology Milan 20141 Italy
Nature Reviews Clinical Oncology London N1 9XW UK
Rappaport Faculty of Medicine Technion Haifa 31096 Israel
Sunnybrook Research Institute Sunnybrook Health Sciences Centre University of Toronto M4N 3M5 Canada
See more in PubMed
Klement G, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. The J Clini Invest. 2000;105(8):R15–24. doi: 10.1172/JCI8829. PubMed DOI PMC
Browder T, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60(7):1878–86. PubMed
Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105(8):1045–7. doi: 10.1172/JCI9872. PubMed DOI PMC
Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7(8):455–65. doi: 10.1038/nrclinonc.2010.82. PubMed DOI
André N, Carré M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol. 2014;11(7):413–31. doi: 10.1038/nrclinonc.2014.89. PubMed DOI
Shaked Y, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science. 2006;313(5794):1785–7. doi: 10.1126/science.1127592. PubMed DOI
Bertolini F, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003;63(15):4342–6. PubMed
Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose ‘chemo-switch’ regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol. 2005;23(5):939–52. doi: 10.1200/JCO.2005.07.093. PubMed DOI
Shaked Y, et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective longterm chemotherapy treatment strategy. Cancer Res. 2005;65(16):7045–51. doi: 10.1158/0008-5472.CAN-05-0765. PubMed DOI
Hasnis E, et al. Anti-bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy. Neoplasia. 2014;16(6):501–10. doi: 10.1016/j.neo.2014.05.011. PubMed DOI PMC
Orlando L, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer. 2006;6:225. doi: 10.1186/1471-2407-6-225. PubMed DOI PMC
Watanabe T, et al. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. J Cclinic Oncol. 2009;27(9):1368–74. doi: 10.1200/JCO.2008.18.3939. PubMed DOI
Bottini A, Generali D, Brizzi MP, Fox SB, et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol. 2006;24:3623–8. PubMed
Ge Y, et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother. 2012;61(3):353–62. doi: 10.1007/s00262-011-1106-3. PubMed DOI PMC
Masuda N, et al. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer. Cancer Chemother Pharmacol. 2014;74(2):229–38. doi: 10.1007/s00280-014-2492-y. PubMed DOI
Brandi G, et al. Durable complete response of hepatocellular carcinoma after metronomic capecitabine. Tumori. 96(6):1028–30. PubMed
Brandi G, et al. Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study. Oncologist. 2013;18(12):1256–7. doi: 10.1634/theoncologist.2013-0093. PubMed DOI PMC
Agrawal A, et al. Response assessment in metronomic chemotherapy: RECIST or PERCIST? Indian J Nucl Med . 2014;29(2):74–80. doi: 10.4103/0972-3919.130285. PubMed DOI PMC
Zapletalova D, et al. Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience. Oncology. 2012;82(5):249–60. doi: 10.1159/000336483. PubMed DOI
Ledzewicz U, Schättler H, et al. On optimal chemotherapy for heterogeneous tumors. J Biological Systems. 2014;22:1–21.
Ledzewicz U, Schaettler H, et al. Optimal and suboptimal protocols for a class of mathematical models of tumor antiangiogenesis. J Theoretical Biol. 2008;252:295–312. doi: 10.1016/j.jtbi2008.02.014. PubMed DOI
Ledzewicz U, Naghneian M, Schaettler H. Optimal Response to Chemotherapy for a Mathematical Model of Tumor-Immune Dynamics. J Math Biol. 2011;64:557–77. doi: 10.1007/s00285-011-0424-6. PubMed DOI
Buyse M, et al. Biomarkers and surrogate end points–the challenge of statistical validation. Nat Rev Clin Oncol. 2010;7(6):309–17. doi: 10.1038/nrclinonc.2010.43. PubMed DOI
Stempak D, et al. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol. 2006;28(11):720–8. doi: 10.1097/01.mph.0000243657.64056.c3. PubMed DOI
Allegrini G, et al. A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. Br J Cancer. 2008;98(8):1312–9. doi: 10.1038/sj.bjc.6604311. PubMed DOI PMC
Allegrini G, et al. Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis. 2012;15(2):275–86. doi: 10.1007/s10456-012-9260-6. PubMed DOI PMC
Orlandi P, et al. VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. Br J Cancer. 2013;109(4):957–64. doi: 10.1038/bjc.2013.398. PubMed DOI PMC
Fontana A, et al. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res. 2009;15(15):4954–62. doi: 10.1158/1078-0432.CCR-08-3317. PubMed DOI
Marchetti V, et al. First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study. Invest New Drugs. 2012;30(4):1725–30. doi: 10.1007/s10637-011-9672-y. PubMed DOI
André N. Has the time come for metronomics in low-income and middle-income countries? Lancet Oncol. 2013;14(6):e239–48. doi: 10.1016/S1470-2045(13)70056-1. PubMed DOI
Ghosh J, et al. Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. Indian J Cancer. 48(4):391–6. n.d. PubMed
Pai PS, et al. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous cell cancers: A matched-pair analysis. Indian J Cancer. 50(2):135–41. PubMed
Traore F. Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01. J Pediatr Hematol Oncol. 2011;33(1):31–4. doi: 10.1097/MPH.0b013e3182018ab8. PubMed DOI
Traore F, et al. Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02. Indian J Cancer. 2013;50(3):250–3. doi: 10.4103/0019-509X.118741. PubMed DOI
Mercurio S, et al. Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma. Acta Neuropathol Commun. 2013;1(1):17. doi: 10.1186/2051-5960-1-17. PubMed DOI PMC
Pasquier E, et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011;2(10):797–809. PubMed PMC
Pasquier E, et al. B-Blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. Br J Cancer. 2013;108(12):2485–94. doi: 10.1038/bjc.2013.205. PubMed DOI PMC
Xu T, et al. Antiangiogenic effect of propranolol on the growth of the neuroblastoma xenografts in nude mice. J Ped Surg. 2013;48(12):2460–5. doi: 10.1016/j.jpedsurg.2013.08.022. PubMed DOI
Wolter JK, et al. Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma. Oncotarget. 2014;5(1):161–72. PubMed PMC
Peyrl A, et al. Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer. 2012;59(3):511–7. doi: 10.1002/pbc.24006. PubMed DOI
Sterba J, et al. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie. 2006;29(7):308–13. doi: 10.1159/000093474. PubMed DOI
Villalba M, et al. From tumor cell metabolism to tumor immune escape. Int J Biochem Cell Biol. 2013;45(1):106–13. doi: 10.1016/j.biocel.2012.04.024. PubMed DOI
Villalba M, et al. Chemical metabolic inhibitors for the treatment of blood-borne cancers. Anticancer Agents Med Chem. 2014;14(2):223–32. PubMed PMC
Fazio N, et al. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. Cancer Treat Rev. 2010;36(Suppl 3):S87–94. doi: 10.1016/S0305-7372(10)70026-8. PubMed DOI
Brizzi MP, et al. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer. 2009;9:388. doi: 10.1186/1471-2407-9-388. PubMed DOI PMC
Berruti A, et al. Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study. BMC Cancer. 2014;14(14):184. doi: 10.1186/1471-2407-14-184. PubMed DOI PMC
Koumarianou A, et al. Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours. Endocr-Relat Cancer. 2012;19(1):L1–4. doi: 10.1530/ERC-11-0287. PubMed DOI PMC
Terzolo M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Eng J Med. 2007;356(23):2372–80. doi: 10.1056/NEJMoa063360. PubMed DOI
Sperone P, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr-Relat Cancer. 2010;17(2):445–53. doi: 10.1677/ERC-09-0281. PubMed DOI
Berruti A, et al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol E. 2012;166(3):451–8. doi: 10.1530/EJE-11-0918. PubMed DOI
Maddaluno L, et al. The adhesion molecule L1 regulates transendothelial migration and trafficking of dendritic cells. J Exp Med. 2009;206(3):623–35. doi: 10.1084/jem.20081211. PubMed DOI PMC
Pantziarka P, et al. The Repurposing Drugs in Oncology (ReDO) Project. Ecancermedicalscience. 2014;8:442. PubMed PMC
Pantziarka P, et al. Repurposing Drugs in Oncology (ReDO)–mebendazole as an anti-cancer agent. Ecancermedicalscience. 2014;8:443. PubMed PMC
Rico MJ, et al. Comparative effectiveness of two metronomic chemotherapy schedules-our experience in the preclinical field. Cancer Invest. 2014;32(3):92–8. doi: 10.3109/07357907.2013.877480. PubMed DOI
Perroud HA, et al. Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients. Future Oncol. 2013;9(3):451–62. doi: 10.2217/fon.12.196. PubMed DOI
Perroud HA, Rico, et al. Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer. Indian J Cancer. 50(2):115–21. PubMed
Patil V, et al. Metronomic chemotherapy in advanced oral cancers. J Cancer Res Ther. 2012;8(Suppl 1):S106–10. PubMed
Patil V, et al. Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers. Clinic Oncol (R Coll Radiol) 2013;25(6):388. doi: 10.1016/j.clon.2013.01.002. PubMed DOI
